NCT05267626
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Sep 19, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 28 versions: 27 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Notable Eligibility criteria expanded, about 39 words
- Primary endpoints: details revised at 1 of 2 entries
- Study sites: 18 to 17
- Secondary endpoints: details revised at 1 of 7 entries
- Notable Primary and study completion pushed from Jun 12, 2026 to Feb 28, 2027v27
- Minor Study sites: 17 to 18v25
- Minor Study sites: 16 to 17v24
Show 22 earlier versionsHide 22 earlier versions
- Minor Site details revised at 2 of 16 sitesv23
- Notable Primary and study completion dates pushed to Jun 12, 2026
- Eligibility criteria expanded, about 110 words
- Study sites: 13 to 16
- Notable Eligibility criteria shortened, about 63 words
- Study description expanded, about 5 words
Notable Eligibility criteria expanded, about 86 wordsv20 Show 4 more changesShow less
- Interventions: AU-007 (Drug), Aldesleukin (Drug), Avelumab (Drug) to AU-007 (Drug), Aldesleukin (Drug), Avelumab (Drug), Nivolumab (Drug)
- Secondary endpoints revised (7)
- Study description shortened, about 11 words
- Study arms: 4 to 5
- Minor Study description shortened, about 11 words
- Study sites revised (13)
- Minor Study sites: 12 to 13v18
Notable Eligibility criteria expanded, about 102 wordsv17 Show 6 more changesShow less
- Primary endpoints revised (2)
- Enrollment target: 136 to 159
- Interventions: AU-007 (Drug), Aldesleukin (Drug) to AU-007 (Drug), Aldesleukin (Drug), Avelumab (Drug)
- Secondary endpoints revised (7)
- Study description expanded, about 18 words
- Study arms: 3 to 4
- Notable Primary completion date: Oct 31, 2024 to Aug 31, 2025
- Eligibility criteria expanded, about 2 words
- Study sites: 10 to 12
- Study completion date: Jan 31, 2025 to Sep 30, 2025
- Notable Enrollment target: 69 to 136
- Primary completion date: Jul 30, 2024 to Oct 31, 2024
- Study completion date: Oct 31, 2024 to Jan 31, 2025
- Site details revised at 1 of 10 sites
- Minor Study sites: 9 to 10v14
- Minor Primary completion date: Jul 2024 to Jul 30, 2024v13
- Minor Study sites: 11 to 9v12
- Notable Primary completion date: Dec 2023 to Jul 2024
- Study sites: 9 to 11
- Study completion date: Mar 31, 2024 to Oct 31, 2024
- Minor Site details revised at 1 of 9 sitesv10
- Minor Study sites: 8 to 9v9
- Minor Study sites: 9 to 8v8
- Notable Eligibility criteria expanded, about 13 wordsv7
- Minor Study sites: 5 to 9v6
- Minor Study sites: 3 to 5v5
- Notable Eligibility criteria expanded, about 2 words
- Enrollment target: 60 to 69
- Study sites: 4 to 3
- Start date changed from estimate of Apr 2022 to Apr 4, 2022
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 3 to 4
- Start date: Mar 31, 2022 to Apr 2022
- Notable Enrollment target: 126 to 60v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
AU-007 (Q2w) administered as a monotherapy sequential ascending doses with each Dose Escalation Cohort (Complete; no longer enrolling)
AU-007 (Q2w) administered in combination with a single dose of aldesleukin with the initial AU-007 dose.
AU-007 administered in combination with aldesleukin, both administered Q2w (Complete; no longer enrolling)
AU-007 and avelumab administered Q2w with a single dose of aldesleukin with the initial AU-007 dose
AU-007 (Q2w) administered in combination with a single dose of aldesleukin with the initial AU-007 dose. Nivolumab will be administered Q4w.
Drugs: AU-007, Aldesleukin, Avelumab, Nivolumab
Sites
17 sites in 2 countries
United States 10, Australia 7